Stay updated with breaking news from Nasdaq Ctic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Needham & Company LLC restated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC – Get Rating) in a research note released on Wednesday morning, Benzinga reports. They currently have a $9.00 target price on the biopharmaceutical company’s stock. Several other research analysts also recently commented on CTIC. TD Cowen decreased their price objective on […]
Shares of CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) traded up 4.2% during trading on Thursday . The company traded as high as $4.25 and last traded at $4.25. 934,835 shares were traded during mid-day trading, a decline of 68% from the average session volume of 2,954,565 shares. The stock had previously closed at $4.08. […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 15,970,000 shares, an increase of 18.3% from the February 28th total of 13,500,000 shares. Based on an average daily volume of 2,950,000 shares, the short-interest ratio is […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
Shares of CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) have earned an average recommendation of “Moderate Buy” from the seven analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target […]